EMA Authorised: Rezzayo (rezafungin) — Mundipharma GmbH

View source ↗

Summary

EMA authorised Rezzayo (rezafungin) for candidiasis and invasive candidiasis, marketed by Mundipharma GmbH.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Candidiasis
• Invasive Candidiasis

Drugs mentioned

• REZZAYO (REZAFUNGIN)

Snippet

Status: Authorised. Therapeutic area: Candidiasis;Candidiasis, Invasive. MAH: Mundipharma GmbH. Decision date: 12/06/2026. Orphan medicine